Martina Takáčová1,2, Mária Bartošová1, Miriam Zaťovičová1, Lucia Škvarková1, Jaromír Pastorek1, Silvia Pastoreková1, Ján Breza3
Despite continuously increasing knowledge of biological and clinical features of kidney cancer, management of tumour patients remains problematic. Use of targeted therapeutics - which is much more effective compared to conventional therapy - is an important step forward; however, further progress can be achieved only through identification and validation of relevant biomarkers for rational stratification of patients and selection of proper treatment strategy. The aim of the proposed study is to clarify clinical importance of carbonic anhydrase IX that is tightly associated with kidney tumours and has a conclusive diagnostic, prognostic, as well as therapeutic potential.